ArticlePDF AvailableLiterature Review

Effect of Nutrients, Dietary Supplements and Vitamins on Cognition: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Authors:

Abstract and Figures

Background Observational studies have suggested that various nutrients, dietary supplements, and vitamins may delay the onset of age-associated cognitive decline and dementia. We systematically reviewed recent randomized controlled trials investigating the effect of nutritional interventions on cognitive performance in older non-demented adults. Methods We searched MEDLINE, CINAHL, Embase, and the Cochrane Library for articles published between 2003 and 2013. We included randomized trials of ≥ 3 months’ duration that examined the cognitive effects of a nutritional intervention in non-demented adults > 40 years of age. Meta-analyses were done when sufficient trials were available. Results Twenty-four trials met inclusion criteria (six omega-3 fatty acids, seven B vitamins, three vitamin E, eight other interventions). In the meta-analyses, omega-3 fatty acids showed no significant effect on Mini-Mental State Examination (MMSE) scores (four trials, mean difference 0.06, 95% CI −0.08 – 0.19) or digit span forward (three trials, mean difference −0.02, 95% CI −0.30 – 0.25), while B vitamins showed no significant effect on MMSE scores (three trials, mean difference 0.02, 95% CI −0.22 – 0.25). None of the vitamin E studies reported significant effects on cognitive outcomes. Among the other nutritional interventions, statistically significant differences between the intervention and control groups on at least one cognitive domain were found in single studies of green tea extract, Concord grape juice, chromium picolinate, beta-carotene, two different combinations of multiple vitamins, and a dietary approach developed for the control of hypertension. Conclusions Omega-3 fatty acids, B vitamins, and vitamin E supplementation did not affect cognition in non-demented middle-aged and older adults. Other nutritional interventions require further evaluation before their use can be advocated for the prevention of age-associated cognitive decline and dementia.
Content may be subject to copyright.
231CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
ABSTRACT
Background
Observational studies have suggested that various nutrients,
dietary supplements, and vitamins may delay the onset of
age-associated cognitive decline and dementia. We system-
atically reviewed recent randomized controlled trials inves-
tigating the effect of nutritional interventions on cognitive
performance in older non-demented adults.
Methods
We searched MEDLINE, CINAHL, Embase, and the Co-
chrane Library for articles published between 2003 and 2013.
We included randomized trials of ≥ 3 months’ duration that
examined the cognitive effects of a nutritional intervention in
non-demented adults > 40 years of age. Meta-analyses were
done when sufcient trials were available.
Results
Twenty-four trials met inclusion criteria (six omega-3 fatty
acids, seven B vitamins, three vitamin E, eight other interven-
tions). In the meta-analyses, omega-3 fatty acids showed no
signicant effect on Mini-Mental State Examination (MMSE)
scores (four trials, mean difference 0.06, 95% CI -0.08 – 0.19)
or digit span forward (three trials, mean difference -0.02, 95%
CI -0.30 – 0.25), while B vitamins showed no signicant
effect on MMSE scores (three trials, mean difference 0.02,
95% CI -0.22 – 0.25). None of the vitamin E studies reported
signicant effects on cognitive outcomes. Among the other
nutritional interventions, statistically signicant differences
between the intervention and control groups on at least one
cognitive domain were found in single studies of green tea
extract, Concord grape juice, chromium picolinate, beta-
carotene, two different combinations of multiple vitamins, and
a dietary approach developed for the control of hypertension.
Conclusions
Omega-3 fatty acids, B vitamins, and vitamin E supplementa-
tion did not affect cognition in non-demented middle-aged and
older adults. Other nutritional interventions require further
evaluation before their use can be advocated for the prevention
of age-associated cognitive decline and dementia.
Key words: nutrition, micro-nutrients, macro-nutrients,
dementia
INTRODUCTION
By 2050, the number of individuals with dementia worldwide
is projected to reach 135 million.(1) Dementia, a devastating
condition, adversely affects the cognitive abilities, indepen-
dence, and quality of life of those affected and leads to health
costs equivalent to those of heart disease and cancer.(2) In
2012, the World Health Organization declared dementia a
public health priority.(3)
The mechanisms underlying the development of age-
associated cognitive decline and dementia are felt to be oper-
ant 10–15 years or more before the development of clinical
symptoms.(4 ,5 ) Recent reports suggest that there is a decline
in the age-specic prevalence of dementia,(6-8) providing
indirect evidence of potentially modiable risk factors.(5)
Effective strategies that can ameliorate the anticipated
Effect of Nutrients, Dietary Supplements and
Vitamins on Cognition: a Systematic Review
and Meta-Analysis of Randomized
Controlled Trials
Scott C. Forbes, PhD1, Jayna M. Holroyd-Leduc, MD4,5, Marc J. Poulin PhD, DPhil1,2, David B. Hogan MD2,3,4,5
1Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, AB; 2Hotchkiss Brain
Institute, Faculty of Medicine, University of Calgary, Calgary, AB; 3Brenda Stafford Foundation Chair in Geriatric Medicine,
Faculty of Medicine, University of Calgary, Calgary, AB; 4Departments of Medicine, Clinical Neurosciences and Community
Health Sciences, Faculty of Medicine, University of Calgary, Calgary, AB; 5Alberta Seniors Health Strategic Clinical
Network, Alberta Health Services, Calgary, AB
DOI:http://dx.doi.org/10.5770/cgj.18.189
SYSTEMATIC REVIEWS/META-ANALYSIS
© 2015 Author(s). Published by the Canadian Geriatrics Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial
No-Derivative license (http://creativecommons.org/licenses/by-nc-nd/2.5/ca/), which permits unrestricted non-commercial use and distribution, provided the original work is properly cited.
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
232
dramatic growth in the number of individuals affected by
dementia brought on by population aging are needed.(3,5 ) In
the absence of curative treatment,(9) preventing or postponing
the onset of dementia is of critical importance.(5) A ve-year
delay in the development of Alzheimer’s disease (the most
common neurodegenerative cause of late-life dementia)
would reduce its prevalence by 50%.(10)
While to date no interventions have been shown to
conclusively decrease the risk of age-associated cognitive
decline or the development of Alzheimer’s disease,(9) there
is a large body of evidence from observational studies sug-
gesting that vitamins, nutrients, and dietary supplements
(e.g., omega-3 fatty acids,(11,12) folic acid,(13) vitamins B6,(13)
B12,(13) C,(14,15) D,(16) and E(14,15) may delay the onset of age-
associated cognitive decline and various forms of dementia
including Alzheimer’s disease.(17,18) A variety of mechanisms
including correction of metabolic derangements or dietary
deciencies have been proposed by which they may affect
cognitive health.(19)
The purpose of this systematic review is to summarize
the ndings of recent randomized controlled trials (RCTs)
investigating the cognitive impact of nutritional interven-
tions (e.g., nutrients [including macro-nutrients, vitamins, or
minerals], diet, dietary supplement, fortied food, or medical
food) of three months or longer in middle-aged and older (>
40 years) non-demented adults. We performed meta-analyses
of the effects where possible.
METHODS
The approach outlined in the Cochrane Handbook for
Systematic Reviews of Interventions(20) was followed
and the reporting was done in accordance with PR ISMA
(Preferred Reporting Items for Systematic Reviews and
Meta-Analyses).(21)
Data Sources and Search Strategy
Literature searches were performed in June 2013 on MED-
LINE, Embase, CINAHL, and the Cochrane Database of
Systematic Reviews. For the MEDLINE search, the Medi-
cal Subject headings (MeSH) terms (exploded) Delirium,
Dementia, Amnestic, and Cognitive Disorders with the
subheading “prevention and control” were combined with
the terms Nutrition Assessment, Nutrition Therapy, Diet,
Micronutrients and Food, plus Nutrition as a keyword. De-
lirium, dementia, and other related terms were searched with
the diet therapy subheading as a separate set. A supporting
keyword search was also done: (cognition disorder* or Al-
zheimer* or mild cognitive decline) AND (food* or diet* or
nutrition* or apolipoprotein* or lipoprotein* or micronutri-
ent* or mineral*). Searches were limited to meta-analyses,
systematic reviews, or RCTs performed on middle-aged and/
or older human study populations and published between
2003 and June 2013. Other systematic reviews surveyed the
literature prior to 2006.(22-24) Our systematic review was
intended to update this prior work. We wanted to focus on
those nutritional interventions attracting the greatest current
interest. A concern we had in including older studies was the
change that that has occurred in typical food intake over the
last 20+ years(2 5) as there is evidence that baseline dietary
intake may impact on the effect that dietary supplements have
on cognitive function. The other databases were searched by
similar strategies using terms from their specic thesauri.
The search was not limited to articles written in any specic
language. The full search strategy is attached in Appendix 1.
Other articles included in our systematic review were either
known by the authors or identied by manually searching
the bibliographies of retrieved articles.
Study Selection
Two of the authors independently screened the titles and
abstracts of each of the articles identied in the search for
possible inclusion in our systematic review. Articles were
selected for full-text review if they met the following criteria:
(i) RCT where participants were allocated to either a dietary
intervention (e.g., nutrient [including macro-nutrients, vita-
mins, or minerals], diet, dietary supplement, fortied food,
or medical food) or a control arm; (ii) all participants were
40 years of age or older and judged to have normal cognition
or mild cognitive impairment (note: if it was not explicitly
noted that all cases of diagnosed or suspected dementia were
excluded, a study was not selected for full-text review); (iii)
intervention duration three or more months (to exclude studies
that dealt with the acute effects of nutritional interventions);
and, (iv) included cognition as an outcome measure. Discrep-
ancies were resolved either by consensus or the involvement
of a third author if necessary.
Full-text articles were reviewed independently by two of
the authors for their eligibility of inclusion in the systematic
review. Study quality, based on the procedures used for ran-
domization, allocation concealment and blinding,(20) and ex-
cluding persons with an underlying condition that could affect
cognition, was considered during the study selection process.
Data Extraction
Full-text articles selected for inclusion had the following
information extracted: authors, country where the study
was done, date of publication, information on specic
inclusion and exclusion criteria, sample size, proportion
of total sample that was female, proportion of total sample
completing the study, mean age, other characteristics of the
study population, nutritional intervention used (including
information on dose and frequency of a supplement), dura-
tion of study, intervention and control adherence, outcome
measures, and results. We focused on examining the out-
come measure(s) results as reported for the entire group.
As mean (standard deviation [SD]) change in the cognitive
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
233
outcome(s) from baseline was frequently not reported, we
noted the nal mean value, SD, and number of participants
in each group. If a trial had two or more intervention arms,
combining their data was considered if the arms were judged
similar (e.g., they used the same nutritional intervention
except for dosage)(20) and the same control group was util-
ized. This was done with one study(26) where we pooled
two intervention arms (moderate and higher dosages of the
same nutritional intervention).
Two authors extracted the data independently with any
disagreements resolved by consensus or the involvement of
a third author if necessary.
Assessment of the Risk for Bias in Included Studies
Two of the authors independently assessed and rated the
trials for their risk of bias based on criteria derived from
the Cochrane Handbook for Systematic Reviews of Inter-
ventions.(20) The methods used for randomization and
blinding were examined. A low risk of bias was considered
present when the approach taken was deemed adequate
for both randomization and blinding, moderate if the ap-
proach taken was either unclear or only partially met the
pre-determined criteria for adequacy, and high risk when
these pre-determined criteria were not met. Disagreements
were resolved by consensus or the involvement of a third
author if necessary.
Data Analysis
A meta-analysis was done if three or more studies examined
the same intervention with the same outcome measure. We
did not encounter any situations where two studies examined
the same intervention with the same outcome measure where
a meta-analysis could have been performed. A xed effect
model was used. A summary measure of the mean differ-
ence with a 95% condence interval (CI) was calculated.
Statistical analysis for heterogeneity was assessed using chi-
square test for heterogeneity and the I2 statistic to quantify
total variation across studies attributable to heterogeneity.
Meta-analysis results are presented as forest plots. Funnel
plots of the meta-analyses were visually inspected to look for
evidence of publication bias, but statistical testing was not
done because of the small number (< 10 / meta-analysis) of
included studies. Statistical analyses were performed using
the software program Review Manager (Review Manager
5.2; The Nordic Cochrane Centre, Copenhagen, Denmark).
RESULTS
Study Characteristics
Two hundred and sixty citations, excluding duplicate entries,
were identied as potentially relevant. After the initial screen-
ing of titles and abstracts, 49 full-text articles were retrieved
for detailed review (Figure 1). Twenty-four articles met our
inclusion criteria for the systematic review (Appendix 2 lists
retrieved full-text articles excluded from the systematic re-
view). While most studies had multiple cognitive outcomes,
ten had a single or designated primary outcome.
Six trials examined the effects of omega-3 fatty acid
supplementation (Table 1). Among these studies, there was
a large amount of heterogeneity with regards to the dosage
used (400 mg to 2200 mg) and duration of the intervention (6
months to 3.3 years). Three found a modest benecial effect
on memory and/or executive functioning,(27-29) while the other
three reported none.(26,30,31)
Meta-analyses of omega-3 fatty acid studies were per-
formed for the outcomes of MMSE scores and digit span
forward results (Figure 2(a) and (b)). The summary mean
difference for MMSE scores was non-signicant at 0.06 (95%
CI -0.08 to 0.19, p = .40), and the summary mean difference
for digit span forward was non-signicant at -0.02 (95% CI
-0.30 to 0.25, p = .87).
Seven trials investigated the effects of various combina-
tions of folate, B6 and/or B12 vitamins (Table 2). There was
substantial heterogeneity between trials with regards to dose,
intervention duration (12 weeks to 6.6 years), participant
health status (suffering from or at risk for cardiovascular
disease to healthy community-dwelling individuals), and
cognitive outcomes assessed. Inconsistent results were seen
with some studies reporting modest benets in at least one
cognitive domain,(32-35) while others found no effect.(36-38)
Three studies were pooled to examine the impact on
MMSE scores of folate combined with vitamins B6 and/or B12
(Figure 3). The summary mean difference for MMSE scores
was non-signicant at 0.02 (95% CI -0.22 to 0.25, p = .90).
Three trials investigated vitamin E supplementation
(Table 3). They were relatively large (769 to 6377 participants)
(39-41) and of long duration (3 to 9.6 years). One trial was lim-
ited to participants with amnestic mild cognitive impairment.
(39) No statistically signicant effect on any of the cognitive
outcomes examined was found.(39-41)
Among the other nutritional interventions examined
(Table 4), statistically signicant differences between the in-
tervention and control groups on at least one cognitive domain
were found for green tea extract,(42) Concord grape juice,(43)
chromium picolinate,(44) beta-carotene,(45) two different
combination therapies including multiple vitamins,(46,47) and
a dietary approach developed for the control of hypertension.
(48) No benecial effects were found for calcium carbonate
combined with vitamin D3.(49)
A variety of approaches were used to assess adher-
ence to the nutritional interventions including counting
capsules,(26,27,31,32,35,37,42-44,47) weighing pills,(49) question-
naires,(33,45) diaries,(32,46) interviews,(34,49) and/or blood analy-
ses.(28,30,37,38) All studies reporting on adherence described it
as good or better (e.g., consumption of 2/3+ of all capsules)
with the intervention.(30,31,33,35,37,40,41,49) Two studies did not
attempt to assess adherence.(29,48)
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
234
Risk of Bias and Evidence of Publication Bias
Ten trials were considered low,(26-28,31,34-39) ten moder-
ate,(29,32,33,40- 42,46-49) and four high risk(30,43 -45 ) of bias (Tables
1–4). Funnel plots for each meta-analysis were visually in-
spected and showed no evidence of publication bias.
DISCUSSION
This systematic review and meta-analysis presents data on
recent RCTs of the cognitive impact of nutritional interven-
tions in non-demented middle-aged and older adults. Our main
nding is that there is no convincing evidence of benet for
any of the nutritional interventions included in this review.
Meta-analyses of two nutritional interventions, omega-3 fatty
acids, and select B vitamins (folate, B6 and/or B12) didn’t
demonstrate signicant effects. The promising results of
generally small single studies with moderate to high risk of
bias reporting on other nutritional interventions will require
conrmation.
In general, observational studies have been more positive
than experimental ones. For example, though several obser-
vational studies(50-53) suggest that a high intake of omega-3
might lead to improve cognition, the RCTs examined showed
no benet(26,30,31) or at most a modest one.(27-29) Observa-
tional studies can lead to erroneous conclusions and must be
interpreted cautiously.(54) The risk of a confounding variable
leading to the groups being compared (e.g., those following a
particular diet versus those not) differing in their probability of
the outcome of interest (e.g., developing cognitive problems)
for reasons other than the intervention is a major limitation
with them. This can occur if one is unaware of potential con-
founders, does not measure them, or does not measure them
adequately. In many circumstances, to more rmly establish
causality, a RCT is required.
Biologically plausible mechanisms are present for most
of the nutritional interventions examined. Omega-3 fatty acids
play a critical role in central nervous system development,
structure, and function.(55) Folate, vitamin B6, and/or vitamin
B12 are considered essential for normal brain function as we
Figure 1: Literature Search Flow Diagram
Recordsidentifiedthrough
databasesearching
(n=242)
Screening
Included
Eligibility
Identification
Additionalrecordsidentified
throughothersources
(n=18)
Recordsafterduplicatesremoved
(n=260)
Records screened
(n=260)
Recordsexcluded
(n=211)
foreligibility
Fulltextarticlesexcluded(n=25)
Review/commentaryn=3
Abstract onlyn=1
Patientsagedidnotmeetcriterian=4
Randomizationnotsufficientn=2
Shorttermstud yn=4
Patients w/dementia oruncle arn=7
Notanutritionalordietaryinterventionn=1
Didnotmeasurecognitionn=2
Studyproposaln=1
qualitativesynthesis
quantitativesynthesis
(metaanalysis;
Omega3 n=6;Folate+/
VitaminsB6/12n=7)
FIGURE 1. Literature search ow diagram
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
235
TABLE 1.
Studies of omega-3 fatty acid supplementation on cognitive function
First Author
(year)
Study
Population
(n)
Design and
Duration
Intervention Outcome Measure Results Risk of
Bias
Geleijnse
et al.(30)
N=2,911
coronary heart
disease patients
(22% women);
60–80 yrs.
RCT; 40
mths.
20 g of a margarine that contained
either a supplement (400 mg/d of
EPA–DHA at a ratio of 3:2,
2 g/d of ALA, 400 mg/d of EPA–DHA
plus 2 g/d of ALA (EPA–DHA 1 ALA))
or a placebo (i.e., non-supplemented
margarine)
Global
(MMSE)
↔ Global cognitive decline (Mean ± SD: PLA=28.2±1.7
vs. Omega-3 =28.3±1.6)
High
Lee
et al.(27)
N=36;
(27 women);
>60 yrs.; low
SES with MCI
RCT; 12
mths.
3 x/d 430 mg of DHA and 150 mg
of EPA/d or an isocaloric placebo
(0.6 g linoeic acid)
Memory (Auditory Verbal
Learning Test and Digit span
backward), executive function,
attention, psychomotor speed,
and global (MMSE)
# Digit Span (Mean (95%CI): PLA = 8.0 (6.877 -9.113)
vs. Omega-3 = 9.6 (8.437-10.749);
VR-I (PLA = 23.1 (19.154-26.952) vs.
Omega-3 = 29.2 (25.207-33.269); RAVLT delayed recall
(PLA = 5.0 (3.587-6.312) vs. Omega-3 = 8.1 (6.645-
9.462);
↔ MMSE (PLA = 26.5 (25.6-27.4) vs.
Omega-3 = 26.6 (25.7-27.6); RAVLT immediate recall
(PLA = 40.1 (37.384-42.785) vs.
Omega-3 = 45.5 (42.706-48.291);
VR-II (PLA = 18.0 (12.943-23.143) vs.
Omega-3 = 20.8 (15.564-26.110); CDT (PLA = 7.8
(7.145-8.436) vs. Omega-3 (7.8 (7.142- 8.477); Digit
Symbol substitution
(PLA = 4.9 (3.254-6.634) vs. Omega-3 = 5.5 (3.723-
7.218)
Low
Van de Rest
et al.(26)
N=302
(45% women);
> 65 yrs.
(mean=70 yrs.)
RCT; 26
wks.
1,800 mg/d EPA–DHA,
400 mg/d EPA–DHA or placebo
(high-oleic sunower oil)
Cognitive domains of attention,
sensorimotor
speed, memory,
and executive function
↔ Mean ± SD: Trail Making part A (PLA = 40.9±16.2 vs.
Low Omega-3 = 42.3±14.0 vs. High Omega-3 =
43.4±15.1);
Trail Making Test Part B – Part A / Part A (PLA =
0.66±0.51 vs.
Low Omega-3 = 0.62±0.46 vs. High Omega-3 =
0.73±0.62);
15 Word Learning-immediate recall – 75 words (PLA
= 44.8±9.4 vs. Low Omega-3 = 46.1±10.1 vs. High
Omega-3 = 44.9±9.9);
Digit span Forward (PLA = 8.5±2.0 vs. Low Omega-3 =
8.6±1.8;
High Omega-3 = 8.6±2.0)
Low risk
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
236
TABLE 1.
Continued
First Author
(year)
Study
Population
(n)
Design and
Duration
Intervention Outcome Measure Results Risk of
Bias
Dangour
et al.(31)
N=867
(45% women);
70-79 yrs.
RCT; 2 yrs. 200 mg EPA plus
500 mg DHA/d or placebo
(olive oil)
Primary: California Verbal
Learning Test (CVLT)
Secondary: Cognitive domains
for global cognitive function,
memory, processing speed,
executive function,
global delay score
↔ Mean ± SD: Primary: CVLT
(PLA = 24.4±6.4 vs. Omega-3 = 24.1±6.7)
on any secondary cognitive outcome
Low risk
Yurko-
Mauro
et al.(28)
N=485
(58% women);
≥ 55 yrs.
RCT; 24
wks.
900 mg/d DHA or placebo
(50% corn oil and 50% soy oil)
Primary: CANTAB Paired
Associate Learning -
visuospatial learning,
and episodic memory
Secondary: CANTAB Pattern
and Verbal Recognition
memory, CANTAB Stockings
of Cambridge, CANTAB
spatial working memory,
Frequency of forgetting-10
scale, MMSE
# Mean ± SD: CANTAB Paired Associate Learning
(PLA = 9.7±10.4 vs. Omega-3 = 8.8±9.9);
# Verbal Recognition memory -immediate
(PLA = 10.9±1.4 vs. Omega-3 = 11.0±1.4) and delayed
(PLA = 10.7±1.8 vs. Omega-3 = 10.7±1.8 ) and Stockings
of Cambridge - Executive function
(PLA = 3.7±1.3 vs. Omega-3 = 3.5±1.3);
↔ on any other cognitive outcome: VRM free recall
(PLA = 5.8±2.1 vs. Omega-3 = 5.8±2.1); PRM delayed,
number correct (PLA = 8.8±1.8 vs. Omega-3 = 8.6±2.0);
MMSE (PLA = 27.9±1.9 vs. Omega-3 = 28.0±1.9)
Low
Witte
et al.(29)
N=65
(31% women);
50-75 yrs.
RCT; 26
wks.
2.2 g/d (1320 mg EPA plus
880 mg DHA) or placebo
(sunower oil)
Executive function (phonemic
uency, semantic uency,
TMT-B/TMT-A, Stroop) and
memory (AVLT learning,
delayed recall, recognition,
digit span backwards)
# Executive function#; ↔ memory#
(Data presented as a gure).
Moderate
# = signicantly better (p<.05) in the omega-3 condition; = no difference between omega-3 and control conditions; # = corrected for multiple comparisons; RCT = randomized
controlled trial; EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ALA = alpha-linolenic acid; SES = socio-economic status; MCI = mild cognitive impairment; MMSE =
Mini-Mental State Examination; CVLT = California Verbal Learning Test; CANTAB = Cambridge neuropsychological test automated battery; TMT-A = Trail Making Test part A; TMT-B
= Trail Making Test part B; AVLT = auditory verbal learning task.
Range of scores of each outcome tool: MMSE = 0–30, Digit Span = 1–19, VR-I = 0–11. VR-II = 0–41, RAVLT delayed recall = 0–15, RAVLT immediate = 0–75, Digit Symbol
Substitution = 1–19, CDT = 0–10, Digit Span Forward = 1–16, CVLT = 0–30, CANTAB PAL = 21 potential outcome measures, CANTAB VRM = 5 potential outcome measures,
CANTAB Stockings of Cambridge = 3 potential outcome measures, TMT-A, TMT-B, Stroop are timed in seconds. Higher scores indicate better performance except for TMT-A, TMT-B,
and Stroop (i.e., more time to complete the tasks represents poorer performance).
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
237
age(56) as a result of their effect on homocysteine metabo-
lism(56,57) and other mechanisms.(58,59) Vitamin E and several
of the other nutrients examined are felt to have anti-oxidant
effects. Long-term oxidative stress has been implicated in the
pathogenesis of cognitive decline and dementia.(60) Consump-
tion of anti-oxidants, such as vitamin E, could potentially
decrease free radical mediated damage in neuronal cells and
reduce beta amyloid toxicity.(61) An in vitro model of green
tea extract was found to attenuate cell death induced by beta
amyloid.(62) Insulin resistance is associated with cognitive
impairment,(63) and chromium may improve insulin sensitiv-
ity.(64) Determining, though, how much weight to give these
purported mechanisms is difcult, cannot be done in isola-
tion from other forms of evidence (e.g., clinical studies), and
ultimately is often subjective.(65)
B vitamins have attracted particular interest as a possible
nutritional intervention.(56) Folate acts as a donor of methyl
groups in a reaction catalyzed by the enzyme methionine
synthase to produce methylcobalamin, which is required for
methylation of homocysteine to methionine.(56) B-vitamin de-
ciency leads to an increase in blood concentrations of homo-
cysteine.(66) High intra-neuronal levels of homocysteine could
disturb brain metabolism and cause cognitive impairment.(56)
Additionally, folate increases nitric oxide availability in the
brain,(58) and deciency of this molecule impairs DNA repair
in neurons and sensitizes neurons to oxidative damage and
the toxicity of amyloid beta-peptide.(59) A cohort study of 965
older adults demonstrated a lower incidence of Alzheimer’s
disease in the highest quartile of total dietary folate intake
after controlling for other factors.(67) We identied seven
RCTs investigating the inuence of B vitamins on cognition
(Table 2). Our meta-analysis showed no signicant effect of
supplementation on MMSE scores. One study did show better
cognitive performance with active therapy but only in women
with low baseline dietary folate intake.(33) Future RCTs should
consider initial nutritional status, as benets may be limited
to those with relative deciencies.(33)
Our ndings are congruent with the previous systematic
reviews. While Manders et al.,(22) in an examination of the
available literature on the cognitive effects of nutritional
supplements in older individuals concluded that their use
might lead to improvements without causing any harm, the
two more recent systematic reviews on this topic found little
if any evidence of a benecial effect.(23,24)
A number of systematic reviews have dealt with specic
nutritional interventions. One examined population-based
cohort studies of anti-oxidant nutrients and reported a possible
effect on age-related cognitive decline though the available
evidence was limited.(68) Recent Cochrane systematic reviews
concluded that both omega-3(69) and folate vitamin B12)(70)
had no consistent benecial effect on cognitive functioning
in healthy older individuals.
Limitations of this review include the limited extent
and quality of the available literature. Even when there are a
number of studies dealing with the same nutritional interven-
tion, the results do not necessarily show a consistent picture.
While this may be due to differences in study population and/
or outcome measures, an issue requiring attention is the vari-
ability in the composition, dose, duration, and timing (during
the participant’s life span) of the intervention. For example,
the ratio of omega-6 to -3 may be an important consideration
for omega-3 trials.(71) There is increasing evidence that a
A
B
FIGURE 2. Meta-analyses of polyunsaturated omega-3 studies for the outcomes of (A) Mini-Mental State Examination (MMSE) score and
(B) digit span forward
A
B
Figure2AandB.
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
238
TABLE 2.
Studies of B vitamins (vitamin B6, vitamin B12, and folate) on cognitive function
First author
(year)
Study Population (n) Design and
Duration
Intervention Outcome Measure Results Risk of Bias
Ford
et al.(32)
N=299 hypertensive
males; >75 yrs.
RCT (computer
generated random
permuted blocks);
2 yrs.
400 μg B12, 2 mg
folic acid, and 25 mg
B6 or placebo
Primary: ADAS-cog.
Secondary: CVLT, MMSE,
Digit Cancellation Test,
Clock Drawing Test, TICS
Primary: (Mean change ± SD (PLA = -0.8±4.0 vs. B
vitamins = -0.7±3.4) ↔ ADAS-cog Secondary: ↔
Clock Drawing Test, and MMSE; # Digit Cancellation
test @ 12 mths; # CVLT @ 24 mths; ↔ in cognitive
impairment and dementia risk over 8-yr follow-up
Moderate
Kang
et al.(33)
N=2009 women with
CVD or vascular
risk factors
RCT; 6.6 yrs. of
treatment and 5.4
yrs. of follow up
Folic acid 2.5 mg,
Vitamin B6 50 mg,
Vitamin B12 1 mg/d
or placebo
Primary: Global cognitive
composite score
Secondary: Verbal memory
composite score; TICS; Category
Fluency
↔ Mean change in global score (95%CI):
Cognitive decline = 0.03 (-0.03-0.08);
↔ Verbal memory; TICS; Category uency
Moderate
Sub-group analysis: # cognition in women
with low baseline intake of B vitamins
van Uffelen
et al.(36)
N=152 (44%
women); 70-80 yrs.;
community dwelling
RCT; 1 yr. 2X2 factorial design:
2x/wk. moderate
exercise; 2x/wk. low
exercise with either
5 mg folic acid,
0.4 mg vitamin B12,
50 mg vitamin B6
or placebo
MMSE, Verbal Fluency Test,
Digit symbol substitution test, and
Abridged Stroop Color Word Test
↔ MMSE: Men: PLA = 29 (28-29) vs. B vitamins = 28
(27-30), Women: PLA = 29 (27-30) vs. B vitamins = 29
(27-30); AVLT 1-5 – words: Men: PLA = 31.5±9.3 vs. B
vitamins = 29.1±8.9, Women: PLA = 31.2±6.6 vs.
B vitamins = 33.7±10); DSST: Men: PLA = 38.1±9.1 vs.
B vitamins = 36.2±12.1, Women: PLA = 33.5±7.7 vs.
B vitamins = 36.6±10.3); Verbal Fluency Test:
Men: PLA = 36.0±13.3 vs. B vitamins 31.8±10.3,
Women: PLA = 36.7±12.1 vs. B vitamins = 33.8±10.1)
Low
Walker
et al.(34)
N=900 with elevated
psychological
distress (60%
women); 60-74 yrs.
RCT; 2 yrs. 400 μg folic acid +
100 μg vitamin B-12
or Placebo
Telephone interview for Cognitive
Status-Modied (TICS-M),
processing speed, and informant
questionnaire on cognitive decline
# In cognitive function
(immediate and delayed memory):
Data presented as gures
Low
McMahon
et al.(37)
N=276
(44% women);
> 65 yrs.
RCT; 2 yrs. Folate (1 mg) and
vitamins B12
(500 μg) and
B6 (10 mg)
or placebo
Global cognition (MMSE);
Rey Auditory Verbal Learning
Test; Verbal and Semantic Fluency;
Processing Speed; Reasoning
Ability
↔ Mean ± SD: MMSE (PLA = 29.32±1.10 vs.
B vitamins = 29.29±1.41); Wechsler Paragraph Recall
test (PLA = 20.76±7.21 vs. B vitamins = 18.67±6.55);
Category Word Fluency test (PLA = 68.78±13.71 vs.
B vitamins = 65.72±14.96); Rey Auditory Verbal
Learning (PLA 44.22±9.90 vs. B vitamins = 43.90±9.70);
Raven’s Progressive Matrices (PLA = 11.90±3.05
vs. B vitamins = 11.60±2.92); Controlled Oral Word
Association (PLA = 41.00±12.44 vs.
B vitamins = 40.11±14.08)
Low
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
239
TABLE 2.
Continued
First author
(year)
Study Population (n) Design and
Duration
Intervention Outcome Measure Results Risk of Bias
De Jager
et al.(35)
N=223
(64% women);
≥70 yrs.
RCT; 2 yrs. 0.8 mg folic acid,
0.5 mg vitamin B12,
20 mg vitamin B6 or
Placebo (vitamin free
tablets)
MMSE, HVLT-DR; episodic
memory, semantic memory,
executive function (CLOX), and
cognitive decline (IQCODE)
↔ MMSE, HVLT-DR or Category Fluency;
# Executive Function; $ Cognitive decline (i.e., slow
the rate of cognitive decline): data presented for
sub-analyses only.
Low
Stott
et al.(38)
N=185
(52% women);
> 65 yrs. with
ischemic disease
RCT; 12 wks. Folic acid (2.5 mg)
plus vitamin B-12
(500 μg), vitamin B-6
(25 mg) and riboavin
(25 mg) or placebo
Letter Digit Coding Test;
TICS-M
Mean change ± SD: ↔ Letter Digit Coding test
(PLA = 1.0±3.2 vs. B vitamins = -1.2±5.6) and
TICS-M (PLA = -0.4±2.7 vs. B vitamins = 0.7±3.8)
Low
# = signicantly better (p<.05) in the B-vitamin condition; ↔ = no difference between B-vitamin and control conditions; $ = signicantly lower (p<.05) in the B-vitamin condition;
RCT = randomized controlled trial; ADAS-cog = Alzheimer’s disease assessment scale – cognition; MMSE = Mini-Mental State Examination; TICS = telephone interview for
cognitive status; TICS-M = telephone interview for cognitive status – modied; CVLT = California Verbal Learning Test; CVD = cardiovascular disease; HVLT-DR = Hopkins Verbal
Learning Test – Delayed Recall; CLOX = Clock Drawing Task; IQCODE = Informant Questionnaire on Cognitive Decline in the Elderly.
Range of scores of each outcome tool: ADAS-Cog = 0-70, CDR = 0-5, MMSE = 0-30, CVLT = 0-30, TICS-M = 0-30, AVLT immediate = 0-75, AVLT delayed = 0-15, DSST and
Verbal Fluency Test = number of correct responses. Higher scores indicate better performance except for ADAS-cog.
FIGURE 3. Meta-analysis of folate, B6, and B12 studies for the outcome of Mini-Mental State Examination (MMSE) score
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
240
lifetime of accumulated exposures are predictive of cogni-
tive function in late-life.(4) An intervention limited to later in
the person’s life may be beyond the critical period when it
may be benecial. More thought about the inuence of the
specic characteristics of the intervention is needed during
the planning stage of these studies. Also relatively neglected
is assessing the initial nutritional status of participants. Ben-
ets may be limited to those with relative deciencies.(72) In
one of the B vitamin studies reviewed,(33) better cognitive
performance was seen with active therapy but only in women
with low baseline dietary folate intake. Another issue might
be the relative insensitivity of the outcome measures utilized
(e.g., MMSE).
Recent research suggests that considering the per-
son’s “whole” diet may be needed to better understand the
nutrient-cognition link.(7 3) Supplements cannot replicate
the complexity of natural food and provide all its potential
benets. Conducting rigorous long-term studies of the ef-
fect of diet on cognition will be a difcult challenge.(74)
One of the dietary approaches that might be considered
is caloric restriction. This may have a benecial impact
by increasing insulin sensitivity.(75) One of our included
studies examined a dietary approach developed for hy-
pertension.(48) Risk factors for Alzheimer’s disease and
vascular dementia overlap with those for heart disease.(4,76)
A recent meta-analysis of observational studies found high
adherence to a Mediterranean diet was associated with a
lower risk of developing cognitive impairment,(7 7,78) but no
interventional studies that met our inclusion criteria were
found. While the PREDIMED-Navarra investigators found
small but statistically signicant differences in favour of
those assigned to a Mediterranean diet supplemented with
TABLE 3.
Studies of vitamin E supplementation on cognitive function
First author
(year)
Study Population
(n)
Design and
Duration
Intervention Outcome Measure Results Risk of Bias
Kang
et al.(41)
N=2824 women;
> 65 yrs.;
≥ 3 coronary
risk factors
RCT; 5.4 yrs.
follow up time
Vitamin E 402 mg
every other day +
500 mg of vitamin
C daily and 50 mg
of B-carotene every
other day or placebo
Telephone interview
for Cognitive Status-
Modied (TICS-M)
↔ Rates of cognitive
change; data presented as
gures
Moderate
Kang
et al.(40)
N= 6377 women;
> 65 yrs.
RCT;
follow up at
~5.6 yrs. and
at ~9.6 yrs.
Vitamin E (600 IU)
or placebo
Primary:
Global composite score
(TICS)
Mean ± SE: ↔ Global
cognitive scores
(PLA = 0.02±0.01 vs.
Vitamin E = 0.02±0.01);
↔ verbal memory
at both follow-ups
Moderate
Secondary:
Verbal memory
(TICS & East Boston
Memory Test)
Petersen
et al.(39)
N=769
(46% women);
72.9±7.3 yrs.;
Amnestic MCI
RCT; 3 yrs. Vitamin E (2000 IU)
or Donepezil (10 mg)
or placebo
Primary: Possible or
probably AD
Secondary: MMSE;
ADAS-Cog; global CDR;
CDR sum of boxes; Global
Deterioration Scale;
New York University
paragraph-recall test; the
symbol digit modalities
test; category-uency test;
a number cancellation
test; Boston Naming Test;
Digits-backward test; clock
drawing test; maze-tracing
task.
↔ Probability of
progression from MCI
to AD (hazard ratio,
1.02; 95% CI,
0.74 – 1.41); ↔ in any
of the secondary
outcome variables
after 3 yrs.
Low
↔ = no difference between vitamin E and control conditions; RCT = randomized controlled trial; ADAS-cog = Alzheimer’s disease
assessment scale – cognition; MMSE = Mini-Mental State Examination; TICS = telephone interview for cognitive status; TICS-M =
telephone interview for cognitive status – modied; AD = Alzheimer’s disease; CDR = clinical dementia rating.
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
241
TABLE 4.
Studies of other nutritional or dietary supplements on cognitive function
First author
(year)
Study Population
(n)
Design and
Duration
Intervention Outcome Measure Results Risk of
Bias
Park
et al.(42)
N=91 (73% women);
subjective memory
complaints including those
with MCI
RCT (balanced
blocked
randomization); 16
wks.
360 mg of Green Tea Extract
and 60 mg of L-theanine or
placebo (maltodextrin and
lactose)
MMSE-Korean;
Rey-Kim memory test;
Stroop color-word reading test
Mean change ± SD: ↔ Stoop (PLA
= 0.67±2.41 vs. Green Tea Extract =
2.47±12.25); Rey-Kim Memory Test (PLA
= 11.26±9.10 vs. Green Tea Extract =
10.60±10.51)
Moderate
Krikorian
et al.(43)
N=12; (33% women);
78.2±5.0 yrs.
RCT; 12 wks. 100% Concord grape juice
(~6-9 mL/kg) or isocaloric
placebo
Verbal (CVLT) and non-verbal
memory (SPALT)
↑verbal learning (PLA = 33.2 vs. Concord
juice = 38.6); ↔ recall PLA = 5.0 vs.
Concord juice = 7.2)
High
Smith
et al.(48)
N=124 (64% women);
hypertensive;
52.3±9.6 yrs.
RCT; 4 mths Dietary Approaches to
Stop Hypertension (DASH),
DASH + weight management,
or usual diet
Trail making test B-A,
Stroop interference, Digit
span, Verbal Fluency test,
Verbal paired associations,
Word Association, and
Psychomotor speed
# Executive function-memory-learning and
psychomotor speed on DASH + weight
management; # psychomotor speed on
DASH alone: Data presented as gures
Moderate
Krikorian
et al.(44)
N=26 (54% women);
71± 6 yrs.
RCT; 3 mths Chromium picolinate
(1000 mcg) or placebo
Clinical Dementia Rating;
CVLT
↔ Learning rate and retention; # semantic
interference on learning, recall, and
recognition memory tasks: Data presented
as gures
High
Grodstein
et al.(45)
N=5956 (n=1904 mean
treatment time = 1 yr.
[new recruits];
n=4052 mean treatment
time = 18 yrs.
[continuing recruits]);
> 65 yrs.
RCT; New recruits
(1 yr.); Continuing
participants
(18 yrs.)
B-carotene every other day
(50 mg) or placebo
Primary: Global composite
score (global cognition, verbal
memory, and category uency)
Secondary: Verbal memory
score
New recruits: (1 yr. treatment) ↔ Global
composite score and verbal uency
Continuing Participants (18 yrs. treatment):
# global composite score and verbal
memory in the continuing participants
(PLA = -0.024±0.71 vs.
Beta Carotene = 0.023±0.69)
High
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
242
TABLE 4.
Continued
First author
(year)
Study Population
(n)
Design and
Duration
Intervention Outcome Measure Results Risk of
Bias
Rossom
et al.(49)
N=4143;
71 yrs. (65-80); women
RCT; Mean
follow-up of
7.8 yrs.
2 tablets/d (1,000mg of
calcium carbonate and 400 IU
of vitamin D3) or placebo
Primary: development of
dementia or MCI
Primary: ↔ Incidence of cognitive
impairment (Hazard ratio: 1.11, 95% CI,
0.71 – 1.74 for dementia)
Moderate
Secondary: 3MSE, Digit
Span Forward and backwards,
Primary Mental Abilities
Vocabulary Test, Card Rotation
Test, Letter and Semantic
uency test, California Verbal
Learning Test, the Benton
Visual Retention Test, and
Finger Tapping Test
Secondary: ↔ 3MSE; ↔ on any
domain-specic cognitive scores
Wolters
et al.(46)
N=220 women;
60-91 yrs.
RCT; 6 mths Vitamin and mineral capsule
(150 mg vitamin C, 50 mg
magnesium, 36 mg vitamin
E, 34 mg niacin, 16 mg
pantothenic acid, 9 mg
B-carotene, 3.4 mg pyridoxine,
3.2 mg riboavin, 2.4 mg
thiamine, 400 μg folic acid,
200 μg biotin, 60 µg selenium,
and 9 μµg cobalamin) or
placebo (soy oil)
Symbol search test, Wechsler
Adult Intelligence Scale,
and pattern recognition and
intelligence
Mean (5-95th percentiles):
↔ Pattern recognition
(PLA = 7.4 (5.0-10.0) vs.
multi-vitamin = 7.6 (5.0-10.0)) and
intelligence (PLA = 110 (90.0-129) vs.
multi-vitamin = 109 (93.4-131));
# symbol search test (PLA = 33.0 (23-42)
vs. multi-vitamin = 35.0 (25-48)
Moderate
Macpherson
et al.(47)
N=56 women; 64-82 yrs. RCT; 16 wks. Multivitamin (contains folic
acid, B6, B12), antioxidant
and mineral formula with
added herbal and antioxidant
plant extracts (Swiss Women’s
Ultivite 50+) or placebo
Primary: memory and
attention composite score
Secondary: Simple Reaction
Time; Complex Reaction
Time; Immediate and Delayed
Recognition Memory; Stroop
Congruent; Contextual
Recognition Memory;
CVLT-II
Primary data is presented as gures.
# Spatial working memory;
↔ any other cognitive test
Moderate
# = signicantly better (p<.05) in the experimental condition; ↔ = no difference between conditions; RCT = randomized controlled trial; MMSE = Mini-Mental State Examination; IU
= international units; MCI = mild cognitive impairment; TICS-M = telephone interview for cognitive status – modied; CVLT = California Verbal Learning Test.
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
243
extra-virgin olive oil on several cognitive measures after an
average of 6.5 years,(79,8 0) cognitive testing was not done at
baseline. As a result, change in cognition in response to the
intervention could not be evaluated. As well, the testing was
done only on sub-groups of participants randomized at one
PREDIMED recruitment site. Other components of a healthy
lifestyle, such as exercise, may be important modulators of
the relationship between dietary intake and cognition.(81)
Their inuence should also be considered in future research.
Much of the research demonstrating a potential link
between nutrition and cognition is observational, done on
animals, or in vitro and may not be relevant to clinical prac-
tice. Our meta-analyses demonstrated no overall effect of
omega-3 fatty acids or select B-vitamin supplementation on
cognition. Green tea extract, chromium, anti-oxidants, and
the DASH (Dietary Approaches to Stop Hypertension) diet
deserve further exploration but cannot be recommended at
this juncture. Future research should utilize rigorous study
methods that incorporate baseline dietary assessments, con-
sider potential modulation by other components of a healthy
lifestyle, and use common and robust outcome measures.
ACKNOWLEDGEMENTS
The authors gratefully acknowledge the support received
from the Brenda Stafford Centre on Aging (SCF), the Brenda
Strafford Foundation Chair in Geriatric Medicine (DBH), the
Brenda Strafford Foundation Chair in Alzheimer Research
(MJP; SCF) of the University of Calgary, and the Canadian
Institutes of Health Research (Funding Reference Number
MOP-93717; MJ Poulin PI). The funders played no role in
the design and conduct of the study, analysis of the data, or
the drafting of this submission.
CONFLICT OF INTEREST DISCLOSURES
The authors have no competing interests to declare.
REFERENCES
1. Prince M, Guerchet, M, Prina, M. Alzheimer’s Disease Interna-
tional. Policy brief for heads of government: the global impact
of dementia 2013–2050. Alzheimer’s Disease International.
2013. Available at: https://www.alz.co.uk/research/Global
ImpactDementia2013.pdf
2. Hurd MD, Martorell P, Delavande A, et al. Monetary costs of de-
mentia in the United States. New Eng J Med. 2013;368(14):1326–34.
3. International WHO. aAD. Dementia: a public health prior-
ity. 2012. Available at: http://www.who.int/mental_health/
publications/dementia_report_2012/en/
4. Yaffe K, Vittinghoff E, Pletcher MJ, et al. Early adult to mid-life
cardiovascular risk factors and cognitive function. Circulation.
2014;129:1548–50.
5. Larson EB, Yaffe K, Langa KM. New insights into the dementia
epidemic. New Eng J Med. 2013;369(24):2275–77.
6. Schrijvers EM, Verhaaren BF, Koudstaal PJ, et al. Is dementia
incidence declining? Trends in dementia incidence since 1990
in the Rotterdam study. Neurology. 2012;78(19):1456–63.
7. Qiu C, von Strauss E, Bäckman L, et al. Twenty-year changes
in dementia occurrence suggest decreasing incidence in central
Stockholm, Sweden. Neurology. 2013;80(20):1888–94.
8. Matthews FE, Arthur A, Barnes LE, et al. A two-decade com-
parison of prevalence of dementia in individuals aged 65 years
and older from three geographical areas of England: results
of the Cognitive Function and Ageing Study I and II. Lancet.
2013;382(9902):1405–12.
9. Daviglus ML, Bell CC, Berrettini W, et al. National Institutes
of Health State-of-the-Science Conference statement: prevent-
ing Alzheimer disease and cognitive decline. Ann Intern Med.
2010;153(3):176–81.
10. Brookmeyer R, Gray S. Methods for projecting the incidence and
prevalence of chronic diseases in aging populations: application
to Alzheimer’s disease. Stat Med. 2000;19(11-12):1481–93.
11. Morris MC, Evans DA, Bienias JL, et al. Dietary fat intake
and 6-year cognitive change in an older biracial community
population. Neurology. 2004;62(9):1573–79.
12. Kalmijn S, van Boxtel MP, Ocke M, et al. Dietary intake of fatty
acids and sh in relation to cognitive performance at middle
age. Neurology. 2004;62(2):275–80.
13. Haan MN, Miller JW, Aiello AE, et al. Homocysteine, B vita-
mins, and the incidence of dementia and cognitive impairment:
results from the Sacramento Area Latino Study on Aging. Am
J Clin Nutr. 2007;85(2):511–17.
14. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary
intake of antioxidants and risk of Alzheimer disease. JAMA.
2002;287(24):3223–29.
15. Devore EE, Grodstein F, van Rooij FJ, et al. Dietary antioxidants
and long-term risk of dementia. Arch Neurol. 2010;67(7):819–25.
16. Slinin Y, Paudel ML, Taylor BC, et al. 25-Hydroxyvitamin D
levels and cognitive performance and decline in elderly men.
Neurology. 2010;74(1):33–41.
17. Gillette-Guyonnet S, Secher M, Vellas B. Nutrition and neu-
rodegeneration: epidemiological evidence and challenges for
future research. Br J Clin Pharmacol. 2013;75(3):738-55.
18. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, et al.
IANA task force on nutrition and cognitive decline with aging.
J Nutr Health Aging. 2007;11(2):132–52.
19. Swaminathan A, Jicha GA. Nutrition and prevention of Al-
zheimer’s dementia. Front Aging Neurosci. 2014;6:282.
20. Higgins JPT, Green S, editors. Cochrane handbook for sys-
tematic reviews of interventions 5.1.0 (updated March 2011):
The Cochrane Collaboration, 2011. Available from: www.
cochrane-handbook.org
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items
for systematic reviews and meta-analyses: the PRISMA state-
ment. J Clin Epidemiol. 2009;62(10):1006–12.
22. Manders M, de Groot LC, van Staveren WA, et al. Effectiveness
of nutritional supplements on cognitive functioning in elderly
persons: a systematic review. J Gerontol A Biol Sci Med Sci.
2004;59(10):M1041–49.
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
244
23. Jia X, McNeill G, Avenell A. Does taking vitamin, mineral and
fatty acid supplements prevent cognitive decline? A system-
atic review of randomized controlled trials. J Hum Nutr Diet.
2008;21(4):317–36.
24. Williams JW, Plassman BL, Burke J, et al. Preventing Al-
zheimer’s disease and cognitive decline. Rockville (MD):
Agency for Healthcare Research and Quality (US). Evidence
report/technology assessment, No. 193. 2010. 727p. Available
from: http://www.ncbi.nlm.nih.gov/books/NBK47456/.
25. The Consumer Food Trends Series. 2014. Available from:
http://www.worldcat.org/title/consumer-food-trends-dening-
opportunities-for-albertas-agri-food-industry/oclc/802069366.
26. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of sh oil
on cognitive performance in older subjects: a randomized,
controlled trial. Neurology. 2008;71(6):430–38.
27. Lee LK, Shahar S, Chin AV, et al. Docosahexaenoic acid-con-
centrated sh oil supplementation in subjects with mild cognitive
impairment (MCI): a 12-month randomised, double-blind, place-
bo-controlled trial. Psychopharmacology. 2013;225(3):605–12.
28. Yurko-Mauro K, McCarthy D, Rom D, et al. Benecial effects
of docosahexaenoic acid on cognition in age-related cognitive
decline. Alzheimers Dement. 2010;6(6):456–64.
29. Witte AV, Kerti L, Hermannstädter HM, et al. Long-Chain
Omega-3 Fatty Acids Improve Brain Function and Structure
in Older Adults. Cereb Cortex. 2014;24(11):3059-68.
30. Geleijnse JM, Giltay EJ, Kromhout D. Effects of n-3 fatty acids
on cognitive decline: a randomized, double-blind, placebo-con-
trolled trial in stable myocardial infarction patients. Alzheimers
Dement. 2012;8(4):278–87.
31. Dangour AD, Allen E, Elbourne D, et al. Effect of 2-y n-3 long-
chain polyunsaturated fatty acid supplementation on cognitive
function in older people: a randomized, double-blind, controlled
trial. Am J Clin Nutr. 2010;91(6):1725–32.
32. Ford AH, Flicker L, Alfonso H, et al. Vitamins B(12),
B(6), and folic acid for cognition in older men. Neurology.
2010;75(17):1540–47.
33. Kang JH, Cook N, Manson J, et al. A trial of B vitamins and
cognitive function among women at high risk of cardiovascular
disease. Am J Clin Nutr. 2008;88(6):1602–10.
34. Walker JG, Batterham PJ, Mackinnon AJ, et al. Oral folic acid
and vitamin B-12 supplementation to prevent cognitive decline
in community-dwelling older adults with depressive symp-
toms—the Beyond Ageing Project: a randomized controlled
trial. Am J Clin Nutr. 2012;95(1):194–203.
35. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical
outcomes of homocysteine-lowering B-vitamin treatment in
mild cognitive impairment: a randomized controlled trial. Int
J Geriatr Psychiatry. 2012;27(6):592–600.
36. van Uffelen JG, Chinapaw MJ, van Mechelen W, et al. Walking
or vitamin B for cognition in older adults with mild cognitive
impairment? A randomised controlled trial. Br J Sports Med.
2008;42(5):344–51.
37. McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial
of homocysteine lowering and cognitive performance. N Engl
J Med. 2006;354(26):2764–72.
38. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized con-
trolled trial of homocysteine-lowering vitamin treatment
in elderly patients with vascular disease. Am J Clin Nutr.
2005;82(6):1320–26.
39. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and
donepezil for the treatment of mild cognitive impairment. N
Engl J Med. 2005;352(23):2379–88.
40. Kang JH, Cook N, Manson J, et al. A randomized trial of vita-
min E supplementation and cognitive function in women. Arch
Intern Med. 2006;166(22):2462–68.
41. Kang JH, Cook NR, Manson JE, et al. Vitamin E, vitamin C,
beta carotene, and cognitive function among women with or at
risk of cardiovascular disease: The Women’s Antioxidant and
Cardiovascular Study. Circulation. 2009;119(21):2772–80.
42. Park SK, Jung IC, Lee WK, et al. A combination of green tea
extract and l-theanine improves memory and attention in sub-
jects with mild cognitive impairment: a double-blind placebo-
controlled study. J Med Food. 2011;14(4):334–43.
43. Krikorian R, Nash TA, Shidler MD, et al. Concord grape juice
supplementation improves memory function in older adults with
mild cognitive impairment. Br J Nutr. 2010;103(5):730–34.
44. Krikorian R, Eliassen JC, Boespug EL, et al. Improved
cognitive-cerebral function in older adults with chromium
supplementation. Nutr Neurosci. 2010;13(3):116–22.
45. Grodstein F, Kang JH, Glynn RJ, et al. A randomized trial
of beta carotene supplementation and cognitive function in
men: the Physicians’ Health Study II. Arch Intern Med.
2007;167(20):2184–90.
46. Wolters M, Hickstein M, Flintermann A, et al. Cognitive per-
formance in relation to vitamin status in healthy elderly German
women—the effect of 6-month multivitamin supplementation.
Prev Med. 2005;41(1):253–59.
47. Macpherson H, Ellis KA, Sali A, et al. Memory improvements in
elderly women following 16 weeks treatment with a combined
multivitamin, mineral and herbal supplement: A randomized
controlled trial. Psychopharmacology. 2012;220(2):351–65.
48. Smith PJ, Blumenthal JA, Babyak MA, et al. Effects of the
dietary approaches to stop hypertension diet, exercise, and
caloric restriction on neurocognition in overweight adults with
high blood pressure. Hypertension. 2010;55(6):1331–38.
49. Rossom RC, Espeland MA, Manson JE, et al. Calcium and vita-
min D supplementation and cognitive impairment in the women’s
health initiative. J Am Geriatr Soc. 2012;60(12):2197–205.
50. Fotuhi M, Mohassel P, Yaffe K. Fish consumption, long-chain
omega-3 fatty acids and risk of cognitive decline or Alzheimer
disease: a complex association. Nat Clin Pract Neurol.
2009;5(3):140–52.
51. Hooijmans CR, Pasker-de Jong PC, de Vries RB, et al. The
effects of long-term omega-3 fatty acid supplementation on
cognition and Alzheimer’s pathology in animal models of
Alzheimer’s disease: a systematic review and meta-analysis. J
Alzheimers Dis. 2012;28(1):191–209.
52. Cederholm T, Palmblad J. Are omega-3 fatty acids options for
prevention and treatment of cognitive decline and dementia?
Curr Opin Clin Nutr Metab Care. 2010;13(2):150–55.
CANADIAN GERIATRICS JOURNAL, VOLUME 18, ISSUE 4, DECEMBER 2015
FORBES: NUTRITION AND COGNITION
245
53. Muldoon MF, Ryan CM, Sheu L, et al. Serum phospholipid
docosahexaenonic acid is associated with cognitive functioning
during middle adulthood. J. Nutr. 2010;140(4):848–53.
54. Spector R, Vesell ES. Which studies of therapy merit credence?
Vitamin E and estrogen therapy as cautionary examples. J Clin
Pharmacol. 2002;42(9):955–62.
55. Gomez-Pinilla F, Kostenkova K. The inuence of diet and
physical activity on brain repair and neurosurgical outcome.
Surg Neurol. 2008;70(4):333–36.
56. Garcia A, Zanibbi K. Homocysteine and cognitive function in
elderly people. CMAJ. 2004;171(8):897–904.
57. Luchsinger JA, Tang MX, Miller J, et al. Relation of plasma
homocysteine to plasma amyloid beta levels. Neurochem Res.
2007;32(4-5):775–81.
58. Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts
dysfunction of endothelial nitric oxide synthase. Circ Res.
2000;86(11):1129–34.
59. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deciency
and homocysteine impair DNA repair in hippocampal neurons
and sensitize them to amyloid toxicity in experimental models
of Alzheimer’s disease. J Neurosci. 2002;22(5):1752–62.
60. Meydani M, Hernandez-Rodriguez J, Youdim MBH, et al.
Antioxidants and cognitive function. Nutr Rev. 2001;59(8-
2):S75–82.
61. Buttereld DA, Castegna A, Lauderback CM, et al. Evidence
that amyloid beta-peptide-induced lipid peroxidation and its
sequelae in Alzheimer’s disease brain contribute to neuronal
death. Neurobiol Aging. 2002;23(5):655–64.
62. Lee SY, Lee JW, Lee H, et al. Inhibitory effect of green tea
extract on beta-amyloid-induced PC12 cell death by inhibition
of the activation of NF-kappaB and ERK/p38 MAP kinase path-
way through antioxidant mechanisms. Brain Res Mol Brain Res.
2005;140(1-2):45–54.
63. Frölich L, Blum-Degen D, Bernstein HG, et al. Brain insulin
and insulin receptors in aging and sporadic Alzheimer’s disease.
J Neural Transm. 1998;105(4-5):423-38.
64. Hua Y, Clark S, Ren J, et al. Molecular mechanisms of
chromium in alleviating insulin resistance. J Nutr Biochem.
2012;23(4):313–19.
65. Potischman N, Weed DL. Causal criteria in nutritional epide-
miology. Am J Clin Nutr. 1999;69(6):1309S–14S.
66. Lindenbaum J, Rosenberg IH, Wilson PW, et al. Prevalence of
cobalamin deciency in the Framingham elderly population.
Am J Clin Nutr. 1994;60(1):2–11.
67. Luchsinger JA, Tang MX, Miller J, et al. Relation of higher
folate intake to lower risk of Alzheimer disease in the elderly.
Arch Neurol. 2007;64(1):86–92..
68. Rafnsson SB, Dilis V, Trichopoulou A. Antioxidant nutrients
and age-related cognitive decline: a systematic review of popu-
lation-based cohort studies. Eur J Nutr. 2013;52(6):1553–67.
69. Sydenham E, Dangour AD, Lim WS. Omega 3 fatty acid for the
prevention of cognitive decline and dementia. The Cochrane
database of systematic reviews. 2012;6:CD005379.
70. Malouf R, Grimley Evans J. Folic acid with or without vitamin
B12 for the prevention and treatment of healthy elderly and
demented people. The Cochrane database of systematic reviews.
2008(4):CD004514.
71. Loef M, Walach H. The omega-6/omega-3 ratio and dementia
or cognitive decline: a systematic review on human studies and
biological evidence. J Nutr Gerontol Geriatr. 2013;32(1):1–23.
72. Galan P, Briançon S, Favier A, et al. Antioxidant status and
risk of cancer in the SU.VI.MAX study: is the effect of
supplementation dependent on baseline levels? Br J Nutr.
2005;94(1):125–32.
73. Cheung BH, Ho IC, Chan RS, et al. Current evidence on
dietary pattern and cognitive function. Adv Food Nutr
Res. 2014;71:137–63.
74. Katz DL, Meller S. Can we say what diet is best for health?
Annu Rev Public Health. 2014;35:83–103.
75. Gillette-Guyonnet S, Vellas B. Caloric restriction and brain func-
tion. Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):686–92.
76. Sacco RL. Achieving ideal cardiovascular and brain health:
opportunity amid crisis: Presidential Address at the Ameri-
can Heart Association 2010 Scientic Sessions. Circulation.
2011;123(22):2653–57.
77. Psaltopoulou T, Sergentanis TN, Panagiotakos DB, et al. Medi-
terranean diet, stroke, cognitive impairment, and depression: A
meta-analysis. Ann Neurol. 2013;74(4):580–91.
78. Singh B, Parsaik AK, Mielke MM, et al. Association of mediter-
ranean diet with mild cognitive impairment and Alzheimer’s
disease: a systematic review and meta-analysis. J Alzheimers
Dis. 2014;39(2):271–82.
79. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Virgin
olive oil supplementation and long-term cognition: the
PREDIMED-NAVARRA randomized, trial. J Nutr Health Ag-
ing. 2013;17(6):544–52.
80. Martinez-Lapiscina EH, Clavero P, Toledo E, et al. Medi-
terranean diet improves cognition: the PREDIMED-NA-
VARRA randomised trial. J Neurol Neurosurg Psychiatry.
2013;84(12):1318–25.
81. Middleton LE, Kirkland SA, Maxwell CJ, et al. Exercise: a
potential contributing factor to the relationship between folate
and dementia. J Am Geriatr Soc. 2007;55(7):1095–98.
Correspondence to: David B. Hogan, md, HSC-3330 Hospital
Dr. NW, Calgary, AB T2N 4N1, Canada
E-mail: dhogan@ucalgary.ca
... However, it has been determined through systematic reviews AKTUALN NEUROL 2023, 23 (2), p. 41-45 DOI: 10.15557/AN.2023.0007 that using a single supplement, such as vitamin C (Forbes et al., 2015;Jia et al., 2008), vitamin B (Butler et al., 2018Forbes et al., 2015;Jia et al., 2008), vitamin D (Butler et al., 2018), vitamin E (Butler et al., 2018;Forbes et al., 2015;Jia et al., 2008), polyunsaturated fatty acid (Butler et al., 2018;Forbes et al., 2015) or their combination (D'Cunha et al., 2018;Forbes et al., 2015;Jia et al., 2008), does not result in a significant reduction in cognitive decline. However, in 2019, a prospective, randomised, double-blind, placebo-controlled intervention clinical trial found that TwX prevented the progression of mild cognitive impairment (MCI), the pre-dementia stage, cognitive impairment to severe forms of AD (Tadokoro et al., 2019). ...
... However, it has been determined through systematic reviews AKTUALN NEUROL 2023, 23 (2), p. 41-45 DOI: 10.15557/AN.2023.0007 that using a single supplement, such as vitamin C (Forbes et al., 2015;Jia et al., 2008), vitamin B (Butler et al., 2018Forbes et al., 2015;Jia et al., 2008), vitamin D (Butler et al., 2018), vitamin E (Butler et al., 2018;Forbes et al., 2015;Jia et al., 2008), polyunsaturated fatty acid (Butler et al., 2018;Forbes et al., 2015) or their combination (D'Cunha et al., 2018;Forbes et al., 2015;Jia et al., 2008), does not result in a significant reduction in cognitive decline. However, in 2019, a prospective, randomised, double-blind, placebo-controlled intervention clinical trial found that TwX prevented the progression of mild cognitive impairment (MCI), the pre-dementia stage, cognitive impairment to severe forms of AD (Tadokoro et al., 2019). ...
... However, it has been determined through systematic reviews AKTUALN NEUROL 2023, 23 (2), p. 41-45 DOI: 10.15557/AN.2023.0007 that using a single supplement, such as vitamin C (Forbes et al., 2015;Jia et al., 2008), vitamin B (Butler et al., 2018Forbes et al., 2015;Jia et al., 2008), vitamin D (Butler et al., 2018), vitamin E (Butler et al., 2018;Forbes et al., 2015;Jia et al., 2008), polyunsaturated fatty acid (Butler et al., 2018;Forbes et al., 2015) or their combination (D'Cunha et al., 2018;Forbes et al., 2015;Jia et al., 2008), does not result in a significant reduction in cognitive decline. However, in 2019, a prospective, randomised, double-blind, placebo-controlled intervention clinical trial found that TwX prevented the progression of mild cognitive impairment (MCI), the pre-dementia stage, cognitive impairment to severe forms of AD (Tadokoro et al., 2019). ...
Article
Oxidative stress has been proposed as a factor in many conditions, such as Alzheimer’s disease. Moreover, there is a link between oxidative stress and a variety of COVID-19 symptoms. The occurrence of multiple diseases can be ascribed to long-term exposure to heightened oxidative stress impeding the body’s normal homeostatic function. Complications arising from elevated levels of oxidative stress include lipid peroxidation, mitochondrial dysfunction, protein oxidation, damage to deoxyribonucleic acid (DNA), glycoxidation, weakened antioxidant defence, and impaired amyloid clearance. Moreover, oxidative stress leads to the onset of inflammation through an increase in the levels of active inflammatory factors. It is widely accepted that the prolongation of this detrimental cycle contributes to the development of pathological states. Consequently, interruption of the cycle of oxidative stress is imperative to prevent disease onset. Research has primarily focused on individual antioxidants, with an emphasis on vitamins C and E, owing to their significant properties as antioxidants that help reduce oxidative stress. Compared to individual antioxidants, supplements encompassing a harmonious assortment mixture of multiple antioxidants may be more effective in combating various symptoms associated with pre-existing conditions and current health concerns like COVID-19 and Alzheimer’s disease. This review explores the correlation between oxidative stress, COVID-19 infection, and Alzheimer’s disease. Additionally, we suggest the use of Twendee X, a remarkably powerful antioxidant compound, to reduce the rate of cognitive decline in individuals with Alzheimer’s disease. Moreover, Twendee X can prevent and alleviate COVID-19 and its associated symptoms.
... This battery is a well-validated and widely used tool for evaluating cognitive function in healthy individuals and individuals with neurocognitive disorders [50]. Furthermore, this battery has been used in previous studies to assess the effect of dietary supplements on cognitive function [51,52]. ...
... Moreover, our observations support prior research examining the effects of various anti-inflammatory nutraceuticals on BDNF levels. Investigations into anti-inflammatory compounds such as curcumin [51], zinc [52], probiotics [53], polyphenols [54], and carotenoids [55] have provided valuable insights into the potential influence of diverse dietary interventions on BDNF. A systematic review of 48 recent human interventions has reported mixed outcomes on BDNF concentrations for the various dietary interventions [56]. ...
Article
Full-text available
Background: Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator which is naturally produced in the body and found in certain foods. The aim of this study was to assess the effect of a bioavailable formulated form of PEA (Levagen+ ®) on serum BDNF levels and parameters of cognitive function in healthy adults. Methods: A randomised double-blinded placebo-controlled cross-over trial was implemented to measure the effects of a 6-week 700 mg/day course of formulated PEA supplementation versus a placebo. Participants (n = 39) completed pre-and post-assessments of a lab-based cognitive test. Serum samples were collected to measure BDNF concentrations using an immunoassay. Results: A significant increase in serum BDNF levels was found following PEA supplementation compared with the placebo (p = 0. 0057, d = 0.62). The cognition test battery demonstrated improved memory with PEA supplementation through better first success (p = 0.142, d = 0.54) and fewer errors (p = 0.0287; d = −0.47) on the Paired Associates Learning test. Conclusion: This was the first study to report a direct beneficial effect of Levagen+ ® PEA supplementation on memory improvement as well as corresponding increases in circulating neurotrophic marker levels. This suggests that formulated PEA holds promise as an innovative and practical intervention for cognitive health enhancement.
Article
Full-text available
The study of amino acids in neurodietetics is of great importance, since they serve as precursors of neurotransmitters and have a significant effect on the functioning of the nervous system. Amino acids play a key role not only in the synthesis of neurotransmitters but also in maintaining their balance, which directly affects mental health. Evaluation of genetic and metabolic characteristics in amino acid intake will allow personalization of nutrition and prevention of diseases of the nervous system. This approach will provide a targeted impact on neurobiological processes. This review structures information on neuroregulatory amino acids and their sources to identify prospects for neurodietary products aimed at improving cognitive functions and overall psycho-emotional well-being. Amino acids affect neuroregulation, acting as excitatory and inhibitory neurotransmitters. They participate in such very important processes as synaptic plasticity and neuroendocrine regulation. Key amino acids - tryptophan and tyrosine, are necessary for the synthesis of serotonin and dopamine, which are responsible for regulating mood and emotional state. Glycine, serine, arginine and lysine, in turn, regulate the activity of NMDA receptors, which is important for neuroplasticity and memory. Products containing these amino acids (e. g., spirulina and beef neck) can significantly improve neurotransmitter metabolism. It is important to maintain a balance of amino acids in the diet to prevent impaired neurotransmission and to reduce the risk of developing psychiatric and neurological disorders.
Article
An increasing number of cross-sectional studies suggests that diet may impact memory and cognition in healthy older adults. However, randomized controlled trials investigating the effects of whole-diet interventions on memory and cognition in healthy older adults are rather rare, and conflicting results are often reported. Therefore, a systematic review was conducted to compile the current evidence regarding the potential effects of whole-diet interventions on 1) memory and 2) other cognitive outcomes in older adults. Studies that reported on randomized controlled trials with dietary interventions in healthy older adults (≥60 y) were included. Studies utilizing supplements, single food items, or trials in specific patient groups (i.e., neurodegenerative diagnoses) were excluded. For the 23 included articles, the main outcomes examined fell into 1 or more of the following categories: cognitive task-based outcomes related to memory, other cognitive task-based outcomes, and additional outcomes related to cognitive function or disease risk. Three of the studies that investigated dietary interventions alone and 2 multidomain studies showed positive effects on memory function, whereas 5 multidomain interventions and 1 intervention that focused on diet alone showed positive effects on other cognitive outcomes. The effect of randomized, controlled whole-diet interventions on memory and cognitive function in healthy older adults is modest and inconclusive, highlighting the need for more well-designed, sufficiently powered studies. Furthermore, the potential mechanisms by which diet impacts cognition in healthy aging need to be elucidated. This systematic review is registered in PROSPERO as CRD42022329759.
Article
To explore the correlation between periodontal health and cognitive impairment in the older population to provide the evidence for preventing cognitive impairment from the perspective of oral health care in older adults. A comprehensive search was conducted in PubMed, Embase, the Cochrane Library, the Web of Science, the China National Knowledge Infrastructure, Wanfang Data, the China Science and Technology Journal Database, and the China Biomedical Literature Database, to include both cross-sectional and longitudinal cohort studies on the association between periodontal health and cognitive impairment in older adults. The search was completed in April 2023. Following quality assessment and data organization of the included studies, meta-analysis was performed using Review Manager 5.4. Twenty-two studies involving a total of 4,246,608 patients were included to comprehensively assess periodontal health from four dimensions (periodontitis, tooth loss, occlusal support, and masticatory ability), with the outcome variable of cognitive impairment (including mild cognitive impairment, Alzheimer’s disease and all-cause dementia). Meta-analysis showed that, compared to those of periodontally healthy older adults, the risk of cognitive impairment in older adults with poor periodontal health, after adjusting for confounders, was significantly greater for those with periodontitis (OR=1.45, 95% CI: 1.20–1.76, P<0.001), tooth loss (OR=1.80, 95% CI: 1.50–2.15, P<0.001), compromised occlusal support (OR=1.87, 95% CI: 1.29–2.70, P=0.001), and reduced masticatory ability (OR=1.39, 95% CI: 1.11–1.75, P=0.005). The risk of cognitive impairment was higher in older adults with low-dentition than in those with high-dentition. Subgroup analysis revealed older individuals with fewer remaining teeth were at a higher risk of developing cognitive impairment compared to those with more remaining teeth, as shown by the comparison of number of teeth lost (7–17 teeth compared to 0–6 teeth) (OR=1.64, 95% CI: 1.13–2.39, P=0.01), (9–28 teeth compared to 0–8 teeth) (OR=1.13, 95% CI: 1.06–1.20, P<0.001), (19–28 teeth compared to 0–18 teeth) (OR=2.52, 95% CI: 1.32–4.80, P=0.005), and (28 teeth compared to 0–27 teeth) (OR=2.07, 95% CI: 1.54–2.77, P<0.001). In addition, tooth loss in older adults led to a significantly increased risk of mild cognitive impairment (OR=1.66, 95% CI: 1.43–1.91, P<0.001) and all-cause dementia (OR=1.35, 95% CI: 1.11–1.65, P=0.003), although the correlation between tooth loss and the risk of Alzheimer’s disease was not significant (OR=3.89, 95% CI: 0.68–22.31, P=0.13). Poor periodontal health, assessed across four dimensions (periodontitis, tooth loss, occlusal support, and masticatory ability), represents a significant risk factor for cognitive impairment in older adults. The more missing teeth in older adults, the higher risk of developing cognitive impairment, with edentulous individuals particularly susceptible to cognitive impairment. While a certain degree of increased risk of Alzheimer’s disease was observed, no significant association was found between tooth loss and the risk of developing Alzheimer’s disease. Enhancing periodontal health management and delivering high-quality oral health care services to older adults can help prevent cognitive impairment.
Preprint
Full-text available
A comprehensive view of factors associated with AD/ADRD will significantly aid in studies to develop new treatments for AD/ADRD and identify high-risk populations and patients for prevention efforts. In our study, we summarized the risk factors for AD/ADRD by reviewing existing meta-analyses and review articles on risk and preventive factors for AD/ADRD. In total, we extracted 477 risk factors in 10 categories from 537 studies. We constructed an interactive knowledge map to disseminate our study results. Most of the risk factors are accessible from structured Electronic Health Records (EHRs), and clinical narratives show promise as information sources. However, evaluating genomic risk factors using RWD remains a challenge, as genetic testing for AD/ADRD is still not a common practice and is poorly documented in both structured and unstructured EHRs. Considering the constantly evolving research on AD/ADRD risk factors, literature mining via NLP methods offers a solution to automatically update our knowledge map. HIGHLIGHTS We summarized the risk factors for AD/ADRD by reviewing existing meta-analyses and review articles on risk and preventive factors for AD /ADRD. Drawing from this literature review and identified AD/ADRD factors, we explored the accessibility of these risk and preventive factors in both structured and unstructured EHR data. We constructed an interactive knowledge map that can be used to aid in the design of future AD/ADRD studies that aim to leverage large collections of RWD to generate RWE.
Conference Paper
Ensuring the quality and safety of our food is crucial for maintaining our health and well-being. Many plants, including chicory root, wheat bran, Jerusalem artichokes, garlic, onions, and asparagus, contain a kind of dietary fiber called inulin, a soluble dietary fiber known to have a variety of health benefits. These health advantages have been demonstrated, including bettering gut health, lowering the risk of chronic illnesses including diabetes and heart disease, and helping with weight control. High-performance liquid chromatography (HPLC) and mass spectrometry methods like Q-TOF and ELSD are used to examine the inulin content in meals. With the aid of these methods, inulin can be precisely detected and quantified, and its chemical makeup identified. In the area of food bioengineering, chromatography, and inulin analysis have the potential to produce ground-breaking findings. The choice of chromatography column and mobile phase depends on the specific analysis requirements. Researchers can create brand-new functional foods that improve health and ward off chronic diseases by finding and comprehending the features of inulin and other dietary fibers. By accurately measuring inulin content in various foods, chromatography analysis contributes to a better understanding of inulin's role in preventing and managing chronic diseases, facilitating the development of inulin-rich foods for improved health outcomes. In summary, inulin is a beneficial dietary fiber with a wide range of health advantages. Accurately detecting and assessing the inulin content of foods using mass spectrometry and HPLC techniques is essential for making breakthroughs in the field of food bioengineering.
Article
Full-text available
Systematic reviews should build on a protocol that describes the rationale, hypothesis, and planned methods of the review; few reviews report whether a protocol exists. Detailed, well-described protocols can facilitate the understanding and appraisal of the review methods, as well as the detection of modifications to methods and selective reporting in completed reviews. We describe the development of a reporting guideline, the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015). PRISMA-P consists of a 17-item checklist intended to facilitate the preparation and reporting of a robust protocol for the systematic review. Funders and those commissioning reviews might consider mandating the use of the checklist to facilitate the submission of relevant protocol information in funding applications. Similarly, peer reviewers and editors can use the guidance to gauge the completeness and transparency of a systematic review protocol submitted for publication in a journal or other medium.
Article
Full-text available
A nutritional approach to prevent, slow, or halt the progression of disease is a promising strategy that has been widely investigated. Much epidemiologic data suggests that nutritional intake may influence the development and progression of Alzheimer's dementia (AD). Modifiable, environmental causes of AD include potential metabolic derangements caused by dietary insufficiency and or excess that may be corrected by nutritional supplementation and or dietary modification. Many nutritional supplements contain a myriad of health promoting constituents (anti-oxidants, vitamins, trace minerals, flavonoids, lipids, …etc.) that may have novel mechanisms of action affecting cellular health and regeneration, the aging process itself, or may specifically disrupt pathogenic pathways in the development of AD. Nutritional modifications have the advantage of being cost effective, easy to implement, socially acceptable and generally safe and devoid of significant adverse events in most cases. Many nutritional interventions have been studied and continue to be evaluated in hopes of finding a successful agent, combination of agents, or dietary modifications that can be used for the prevention and or treatment of AD. The current review focuses on several key nutritional compounds and dietary modifications that have been studied in humans, and further discusses the rationale underlying their potential utility for the prevention and treatment of AD.
Article
Background: Homocysteine is an independent risk factor for vascular disease and is associated with dementia in older people. Potential mechanisms include altered endothelial and hemostatic function. Objective: We aimed to determine the effects of folic acid plus vitamin B-12, riboflavin, and vitamin B-6 on homocysteine and cognitive function. Design: This was a factorial 2 × 2 × 2, randomized, placebo-controlled, double-blind study with 3 active treatments: folic acid (2.5 mg) plus vitamin B-12 (500 μg), vitamin B-6 (25 mg), and riboflavin (25 mg). We studied 185 patients aged ≥65 y with ischemic vascular disease. Outcome measures included plasma homocysteine, fibrinogen, and von Willebrand factor at 3 mo and cognitive change (determined with the use of the Letter Digit Coding Test and on the basis of the Telephone Interview of Cognitive Status) after 1 y. Results: The mean (±SD) baseline plasma homocysteine concentration was 16.5 ± 6.4 μmol/L. This value was 5.0 (95% CI: 3.8,6.2) μmol/L lower in patients given folic acid plus vitamin B-12 than in patients not given folic acid plus vitamin B-12 but did not change significantly with vitamin B-6 or riboflavin treatment. Homocysteine lowering with folic acid plus vitamin B-12 had no significant effect, relative to the 2 other treatments, on fibrinogen, von Willebrand factor, or cognitive performance as measured by the Letter Digit Coding Test (mean change: -1; 95% CI: -2.3, 1.4) and the Telephone Interview of Cognitive Status (-0.7; 95% CI: -1.7,0.4). Conclusion: Oral folic acid plus vitamin B-12 decreased homocysteine concentrations in elderly patients with vascular disease but was not associated with statistically significant beneficial effects on cognitive function over the short or medium term.
Article
National Institutes of Health (NIH) consensus and stateof-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of 1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality, 2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, 3) questions and statements from conference attendees during open discussion periods that are part of the public session, and 4) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of NIH or the U.S. government. The following statement is an abridged version of the panel’s report, which is available in full at http://consensus.nih.gov/2010 /alzstatement.htm. Alzheimer disease is the most common cause of dementia. It was first described in 1906 by German psychiatrist and neuropathologist Alois Alzheimer, who observed the pathologic hallmarks of the disease—abnormal clumps of protein (-amyloid plaques) and tangled bundles of protein fibers (neurofibrillary tangles)—in the brain of a woman who had experienced memory loss, language problems, and unpredictable behavior. An important breakthrough was the invention of the photomicrograph in the early 1900s by the psychiatrist Solomon Carter Fuller; this key innovation provided a method for taking photographs through the lens of a microscope, allowing visualization of amyloid plaques and neurofibrillary tangles. Since its first description, Alzheimer disease has gone